argenex (NASDAQ:ARGX) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $1,000.00 price target on the stock.
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG
argenx Highlights 2026 Strategic Priorities
argenex (NASDAQ:ARGX) had its price target lowered by analysts at Citigroup Inc. from $1,124.00 to $1,091.00. They now have a "buy" rating on the stock.
argenex (NASDAQ:ARGX) had its price target raised by analysts at Truist Financial Corporation from $950.00 to $1,030.00. They now have a "buy" rating on the stock.